Curated News
By: NewsRamp Editorial Staff
July 21, 2025
NanoViricides' NV-387 Shows Promise as First Measles Treatment
TLDR
- NanoViricides Inc.'s NV-387 offers a groundbreaking advantage by potentially becoming the first drug to treat Measles, with a 130% increase in survival rates in preclinical trials.
- NV-387 works by mimicking human cell features to bind and neutralize viruses, demonstrating dose-dependent efficacy and no toxicity in a lethal respiratory infection model.
- With global Measles cases rising and vaccine coverage declining, NV-387 represents a critical step towards improving global health and saving lives.
- Discover how NanoViricides Inc.'s innovative NV-387 could revolutionize antiviral therapy by targeting over 90% of human pathogens with its unique nanomedicine approach.
Impact - Why it Matters
The development of NV-387 by NanoViricides represents a significant breakthrough in antiviral therapy, especially for Measles, a disease that has seen a resurgence due to declining vaccine coverage. This news is crucial as it highlights the potential for a much-needed therapeutic option in the fight against Measles and other respiratory viral infections, offering hope for better outcomes in cases where vaccines are not an option or have failed to provide immunity.
Summary
NanoViricides, Inc. (NYSE American: NNVC), a leader in the development of broad-spectrum antivirals through host-mimetic nanomedicine, has announced groundbreaking results for its lead drug candidate, NV-387, in the treatment of Measles. Demonstrating a remarkable 130% increase in survival rates in a lethal respiratory infection model using humanized mice, NV-387 has shown no toxicity and dose-dependent efficacy. This innovative drug, which mimics human cell features to neutralize viruses, targets over 90% of human pathogens. With Measles cases on the rise globally and vaccine coverage waning, the urgent need for a therapeutic solution has never been clearer. Dr. Anil R. Diwan, PhD, highlighted the potential of NV-387 to become the first-ever Measles treatment. For more details, the full press release is available here.
NanoViricides is at the forefront of creating nanomaterials for antiviral therapy, with NV-387 being developed for a range of respiratory viral infections, including RSV, COVID-19, and influenza, among others. The company's collaboration with TheraCour Pharma, Inc. underpins its innovative approach to tackling viral diseases. With plans to advance NV-387 into Phase II clinical trials, NanoViricides is paving the way for new treatments in the face of declining vaccine efficacy and emerging viral threats. Discover more about their pioneering work at www.NanoViricides.com.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, NanoViricides' NV-387 Shows Promise as First Measles Treatment
